Providence Medical Technology receives new indication clearance for facet fixation system
Click Here to Manage Email Alerts
Providence Medical Technology has announced FDA clearance of the Cavux facet fixation system for a new indication in the treatment of cervical pseudarthrosis, according to a press release.
The Cavux facet fixation system (FFS) features an integrated cage and screw system to provide facet joint stabilization for the facilitation of spinal fusion. According to the release, the Cavux FFS is now indicated for the treatment of patients who require revision for anterior pseudarthrosis occurring at one level from C3-C7 with autogenous or allogenic bone graft.
“At Providence, our purpose is improving clinical outcomes and preventing surgical failures for high-risk spinal fusion patients,” Jeff Smith, CEO and co-founder of Providence Medical Technology, said in the release. “Corus spinal system, indicated for cervical and lumbar fusion, is the global market leader in tissue-sparing posterior spinal fusion. Cavux FFS delivers powerful stabilization through its unique integrated cage and screw design. Cavux FFS is indicated as an adjunct to [posterior cervical fusion] with Corus spinal system and provides non-segmental instrumentation through a novel design that spans the facet joint interspaces with points of fixation at both ends of the construct,” he added.
Read more about
Click Here to Manage Email Alerts